Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD38 CAR-T cells (Chinese PLA General Hospital)
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD38 CAR-T cells (Chinese PLA General Hospital) is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy designed to target CD38, a transmembrane glycoprotein highly expressed on malignant B-cell acute lymphoblastic leukemia (B-ALL) cells. Developed by researchers at the Chinese PLA General Hospital, this cell-based immunotherapy is specifically intended for patients with relapsed or refractory B-ALL, particularly those who have failed prior CD19-directed CAR-T cell therapies and may have experienced CD19-negative relapse. The therapy involves the genetic modification of a patient's own T cells to express a CAR construct that recognizes CD38, enabling the targeted identification and elimination of leukemic cells. It is currently being evaluated in Phase I/II clinical trials to determine its safety, feasibility, and therapeutic potential in this high-risk patient population.
- Other names
- CD38-targeted CAR-T cellsCD-38-targeted CAR-T cellsCD 38-targeted CAR-T cellsanti-CD38 CAR-T cellsanti-CD-38 CAR-T cellsanti-CD 38 CAR-T cells
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on CD38 CAR-T cells (Chinese PLA General Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD38 CAR-T cells (Chinese PLA General Hospital).